Health100 is designed as a cross-stakeholder digital destination, avoiding closed proprietary architectures to connect ...

In today’s Pharma Pulse, Antengene and UCB ink a $1.18 billion global deal for ATG-201 to target autoimmune diseases, while ...

Esperion Therapeutics has entered into a definitive agreement to acquire Corstasis Therapeutics, a privately held biopharmaceutical company. The acquisition focuses on the integration of Enbumyst™ ...

Eton Pharmaceuticals. Eton Pharmaceuticals expands rare disease portfolio through acquisition of U.S. commercialization rights to HEMANGEOL® (propranolol hydrochloride) oral solution. Eton ...

Thirty telehealth firms received warning letters for illegal promotion of compounded semaglutide/tirzepatide, reflecting an expanded enforcement tempo that now surpasses the prior decade’s letter ...

In today's Pharma Pulse, the FDA expands the pediatric indication for Juxtapid to treat rare homozygous familial hypercholesterolemia, while Novo Nordisk announces a major €432 million investment in ...

SpotSee and Controlant announced a collaboration to enhance pharmaceutical supply chain visibility using integrated ...

Thermal testing can make or break cold chain performance. Join this webinar to learn proven best practices that help eliminate blind spots, validate designs, and protect temperature-sensitive ...

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innov ...

In today’s Pharma Pulse, the FDA grants priority review to a therapy for polycythemia vera, while Novo Nordisk receives expanded pediatric approval for its once-weekly growth hormone.

A conversation with Kenco’s Tim McClatchy explores how pharmaceutical logistics providers are strengthening cybersecurity ...

Global life sciences supply chain conference LogiPharma has announced a brand-new series of interactive formats for 2026 under the leadership of incoming event director, Ben Sharples.